Network-Based Approaches in Drug Discovery and Early Development
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Identification of novel targets is a critical first step in the drug discovery and development process. Most diseases such as cancer, metabolic disorders, and neurological disorders are complex, and their pathogenesis involves multiple genetic and environmental factors. Finding a viable drug target-drug combination with high potential for yielding clinical success within the efficacy-toxicity spectrum is extremely challenging. Many examples are now available in which network-based approaches show potential for the identification of novel targets and for the repositioning of established targets. The objective of this article is to highlight network approaches for identifying novel targets with greater chances of gaining approved drugs with maximal efficacy and minimal side effects. Further enhancement of these approaches may emerge from effectively integrating computational systems biology with pharmacodynamic systems analysis. Coupling genomics, proteomics, and metabolomics databases with systems pharmacology modeling may aid in the development of disease-specific networks that can be further used to build confidence in target identification.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A note on two problems in connexion with graphs
Dijkstra, E. W. (1959) · Numerische Mathematik · doi:10.1007/bf01386390 · Cited by 29,065
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Caspi, R., Billington, R., Ferrer, L., Foerster, H., Fulcher, C. A., Keseler, I. M., Kothari, A., Krummenacker, M., Latendresse, M., Mueller, L. A., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1164 · Cited by 3,395
Goh, K.-I., Cusick, M. E., Valle, D., Childs, B., Vidal, M., & Barabási, A.-L. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701361104 · Cited by 3,242
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104 · cited 1×
“57 This mutation can be detected by assay, but such direct measures are not always available.”
BackgroundHolme, P., & Saramäki, J. (2012) · Physics Reports · doi:10.1016/j.physrep.2012.03.001 · Cited by 2,736
KEGG for representation and analysis of molecular networks involving diseases and drugs
Kanehisa, M., Goto, S., Furumichi, M., Tanabe, M., & Hirakawa, M. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkp896 · Cited by 2,322 · cited 1×
“28,29 The Kyoto Encyclopedia of Genes and Genomes databases include metabolic and signal transduction information for several species.”
BackgroundPredicting new molecular targets for known drugs
Keiser, M. J., Setola, V., Irwin, J. J., Laggner, C., Abbas, A. I., Hufeisen, S. J., Jensen, N. H., Kuijer, M. B., Matos, R. C., Tran, T. B., et al. (2009) · Nature · doi:10.1038/nature08506 · Cited by 1,667 · cited 1×
“For drug target identification, this can involve assuming drug modulation or elimination of a network node but more likely involves changing a combination of nodes or edges 2,38–41 to achieve some pharmacological response.”
BackgroundDrug target identification using side-effect similarity
Campillos, M., Kuhn, M., Gavin, A.-C., Jensen, L. J., & Bork, P. (2008) · Science · doi:10.1126/science.1158140 · Cited by 1,248 · cited 1×
“36,37”
Roth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1346 · Cited by 1,155
Shortest paths algorithms: Theory and experimental evaluation
Cherkassky, B. V., Goldberg, A. V., & Radzik, T. (1996) · Mathematical Programming · doi:10.1007/bf02592101 · Cited by 899
A side effect resource to capture phenotypic effects of drugs
Kuhn, M., Campillos, M., Letunic, I., Jensen, L. J., & Bork, P. (2010) · Molecular Systems Biology · doi:10.1038/msb.2009.98 · Cited by 899
Gene regulatory network inference: Data integration in dynamic models—A review
Hecker, M., Lambeck, S., Toepfer, S., van Someren, E., & Guthke, R. (2009) · Biosystems · doi:10.1016/j.biosystems.2008.12.004 · Cited by 755
Pathway Tools version 13.0: integrated software for pathway/genome informatics and systems biology
Karp, P. D., Paley, S. M., Krummenacker, M., Latendresse, M., Dale, J. M., Lee, T. J., Kaipa, P., Gilham, F., Spaulding, A., Popescu, L., et al. (2010) · Briefings in Bioinformatics · doi:10.1093/bib/bbp043 · Cited by 694
Haffner, S. M. (1990) · JAMA · doi:10.1001/jama.1990.03440210043030 · Cited by 668 · cited 1×
“64,65 Therefore, the glucose-lowering effects of compounds such as rosiglitazone need to be balanced against a potential increase in the risk of heart failure.”
BackgroundA robustness-based approach to systems-oriented drug design
Kitano, H. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2195 · Cited by 488 · cited 1×
“60”
Systems pharmacology for drug discovery and development: paradigm shift or flash in the pan?
Vicini, P., & van der Graaf, P. H. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.40 · Cited by 108
Cited by
Network‐based Approaches in Pharmacology
Boezio, B., Audouze, K., Ducrot, P., & Taboureau, O. (2017) · Molecular Informatics · doi:10.1002/minf.201700048 · Cited by 359
Computational/in silico methods in drug target and lead prediction
Agamah, F. E., Mazandu, G. K., Hassan, R., Bope, C. D., Thomford, N. E., Ghansah, A., & Chimusa, E. R. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbz103 · Cited by 328
Machine and deep learning approaches for cancer drug repurposing
Issa, N. T., Stathias, V., Schürer, S., & Dakshanamurthy, S. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.011 · Cited by 274
Combination therapeutics in complex diseases
He, B., Lu, C., Zheng, G., He, X., Wang, M., Chen, G., Zhang, G., & Lu, A. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12930 · Cited by 112
“These methods can be used to explore the therapeutic mechanisms underlying drug treatment at the molecular level [73].”
Hampel, H., Vergallo, A., Giorgi, F. S., Kim, S. H., Depypere, H., Graziani, M., Saidi, A., Nisticò, R., & Lista, S. (2018) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2018.06.001 · Cited by 68
Metadata
- Authors
- Harrold, J. M., Ramanathan, M., & Mager, D. E.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2013-09-11
- Volume
- 94
- Issue
- 6
- Pages
- 651-658
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2000417339
- Cited by
- 96
- References
- 17
- FWCI
- 10.98
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.